Enfuvirtide
Also known as: Fuzeon, T-20, DP-178
Enfuvirtide (also called Fuzeon or T-20) is an FDA-approved HIV fusion inhibitor. Enfuvirtide is a thirty-six-amino-acid peptide derived from the HR2 region of the HIV-1 envelope glycoprotein gp41. During viral entry gp41 must fold so that its HR1 and HR2 regions pack into a six-helix bundle, and it is the energy of that collapse that pulls the viral and cell membranes together.
For research use only.
Key Facts
- CAS
- 159519-65-0
- Molecular Weight (MW)
- 4491.4 g/mol
- Half-life
- About 3.8 hours after a 90 mg subcutaneous dose
- FDA status
- Approved
- Evidence level
- FDA Approved
- Human dose established
- Yes
- Administration Route
- Subcutaneous
- Frequency
- Twice daily
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
- Targets
- HIV-1 gp41
Research summary
FDA-approved HIV-1 fusion inhibitor (Fuzeon) for treatment-experienced patients. 90 mg subcutaneous twice daily with other antiretrovirals.
Research evidence
- Regulatory review (FDA label)2 reviewed sources
- Controlled human trials1 reviewed source
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studiesNone in reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's Enfuvirtide profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Enfuvirtide dosage evidence
Enfuvirtide has an FDA-approved human dosage, as Fuzeon, for treatment-experienced people with HIV-1 who still have detectable virus despite ongoing antiretroviral therapy, always combined with other antiretrovirals. The label's adult dose is 90 mg (1 mL) injected under the skin twice daily; children weighing at least 11 kg receive 2 mg/kg twice daily, up to 90 mg twice daily.
| Human dosing established | Yes |
|---|---|
| Route | Subcutaneous |
| Frequency | Twice daily |
| Duration studied | Long-term, as part of combination antiretroviral therapy |
| Half-life | About 3.8 hours after a 90 mg subcutaneous dose |
| Evidence level | FDA Approved |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| FDA label — Fuzeon, adultsFDA-approved label · FDA prescribing information | Treatment-experienced adults with HIV-1 replication despite ongoing antiretroviral therapy | 90 mg (1 mL) | Subcutaneous (upper arm, front of thigh or abdomen) | Twice daily | Ongoing, with other antiretrovirals | Treatment of HIV-1 infection | FUZEON (enfuvirtide) for injection — FDA prescribing information, revised 8/2019 (Drugs@FDA) |
| FDA label — Fuzeon, childrenFDA-approved label · FDA prescribing information | Treatment-experienced children with HIV-1 weighing at least 11 kg | 2 mg/kg, up to 90 mg; the label's weight table runs from 27 mg (11–15.5 kg) to 90 mg (42.6 kg and over) | Subcutaneous | Twice daily | Ongoing, with weight checked and the dose adjusted periodically | Treatment of HIV-1 infection | FUZEON (enfuvirtide) for injection — FDA prescribing information, revised 8/2019 (Drugs@FDA) |
| TORO 1 — phase 3, NEJM 2003Clinical trial · Randomised, open-label phase 3 trial | Adults with multidrug-resistant HIV-1 after at least six months of three drug classes (501 randomised) | Enfuvirtide with an optimised background regimen of three to five antiretrovirals, or the background regimen alone (dose not stated in the indexed abstract) | Not stated in the indexed abstract | Not stated in the indexed abstract | 24 weeks to the primary endpoint | Mean viral load fell by 1.696 log10 copies/mL with enfuvirtide versus 0.764 with the background regimen alone; injection-site reactions in 98% of patients and more pneumonia with enfuvirtide | Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003. |
Where sources disagree
- Fuzeon has no current label on DailyMed, and Drugs@FDA lists the product as discontinued; the dosing above is from its last FDA prescribing information (August 2019) on Drugs@FDA.
- The label reports local injection-site reactions in 98% of trial participants and an increased rate of bacterial pneumonia compared with the control arm; it also warns about hypersensitivity reactions and post-injection bleeding.
- The label says each single-dose vial must be reconstituted only with the 1 mL of Sterile Water for Injection provided in its kit.
Handling & administration
- Reconstitution Guide
- Reconstitute 90 mg vial with 1.1 mL sterile water for injection
- Injection Sites
- AbdomenArmThigh
- Concentration Example
- 90 mg vial + 1.1 mL → 90 mg/mL
- Timing Notes
- Inject subcutaneously in upper arm, anterior thigh, or abdomen, rotating injection sites
- Expected Onset
- Viral load reduction typically seen within 2-4 weeks
Sequence & molecular data
| Molecular formula | C204H301N51O64 |
|---|---|
| Molecular weight | 4491.4 g/mol |
| CAS number | 159519-65-0 |
| Half-life | ~3.8 hours (sc) |
| Appearance | Lyophilized powder for subcutaneous injection |
| Formulation | Lyophilized Powder |
| PubChem CID | 16130199 |
| FDA UNII | 19OWO1T3ZE |
| ChEMBL | CHEMBL525076 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Enfuvirtide is a thirty-six-amino-acid peptide derived from the HR2 region of the HIV-1 envelope glycoprotein gp41. During viral entry gp41 must fold so that its HR1 and HR2 regions pack into a six-helix bundle, and it is the energy of that collapse that pulls the viral and cell membranes together. Enfuvirtide binds the exposed HR1 groove in the transient pre-hairpin intermediate and occupies the site HR2 would use, preventing the bundle from forming and arresting fusion before the viral core enters the cell. Because it acts outside the cell on a structural rearrangement rather than on an enzyme, it retains activity against virus resistant to reverse transcriptase and protease inhibitors.
Origin
Synthetic peptide corresponding to gp41 HR2.
Targets
Studies
Research statistics
804 PubMed publications · 32.0% human clinical research · 40 registered trials
Counts of published research through 2026-11-15, not evidence that it works. Publications by year, study types and trials · How publications are counted
Regulatory & research status
Enfuvirtide is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.
| FDA status | Approved |
|---|---|
| Availability | Prescription-Only |
| WADA (sport) | Permitted |
| Library classification | FDA-Approved |
How FDA approval, compounding and research-only status differ
Benefits
Enfuvirtide side effects
The effects below are drawn from Enfuvirtide's prescribing information, which lists the full adverse-reaction data.
Side Effects
- Injection-site reactions (very common)
- Pneumonia signal
- Hypersensitivity
Storage & stability
This compound is not supplied as a powder to be mixed, so the freeze-dried powder and reconstitution handling described for research peptides does not apply. Storage conditions are product-specific: follow the label or packaging of the product itself.
Enfuvirtide: frequently asked questions
What is Enfuvirtide?
FDA-approved HIV-1 fusion inhibitor (Fuzeon) for treatment-experienced patients. 90 mg subcutaneous twice daily with other antiretrovirals.
How does Enfuvirtide work?
Enfuvirtide is a thirty-six-amino-acid peptide derived from the HR2 region of the HIV-1 envelope glycoprotein gp41. During viral entry gp41 must fold so that its HR1 and HR2 regions pack into a six-helix bundle, and it is the energy of that collapse that pulls the viral and cell membranes together.
Is Enfuvirtide FDA approved?
Yes. Enfuvirtide is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.
What is the half-life of Enfuvirtide?
Reported half-life for Enfuvirtide is ~3.8 hours (sc). Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
Is Enfuvirtide banned in sport?
Enfuvirtide is recorded here as permitted in sport. Anti-doping status is revised annually, so athletes subject to testing should confirm against the current WADA Prohibited List before use.
What peptides are similar to Enfuvirtide?
Compounds most often compared with Enfuvirtide include Angiotensin II, Cetrorelix, Corticorelin and Cosyntropin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- FDA label — FuzeonExternal reference
- Enfuvirtide, 2012External reference
- Multifaceted action of Fuzeon as virus-cell membrane fusion inhibitor — Biochim Biophys Acta, 2011External reference
- Fuzeon-induced collagenophagic granuloma: a peculiar granulomatous injection site reaction to Fuzeon--a case report and review of literature — Int J Surg Pathol, 2010External reference
- [Spanish recommendations for proper use of enfuvirtide] — Enferm Infecc Microbiol Clin, 2007External reference
- Enfuvirtide, 2006External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 2
This Enfuvirtide profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Enfuvirtide research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →